Palisade Bio (NASDAQ:PALI) named JD Finley, CFO, as interim CEO, replacing Thomas Hallam, Ph.D., effective Oct. 10.
In a statement, James Neal, chairman of Palisade, said Dr. Hallam was “instrumental in the development LB1148 and we thank him for his contributions to the company and wish him the best in his future endeavors.”
LB1148, the company’s lead program, is a broad-spectrum serine protease inhibitor, with the potential to neutralize digestive enzymes, potentially reducing intestinal damage.
Mr. Finley said, “I am a strong believer in the promise of LB1148 for the potential treatment of acute and chronic gastrointestinal complications.”
